WilmerHale Represents Underwriters in $230.5M Celldex Therapeutics Offering

• 12.8.2023

WilmerHale represented the underwriters in the public offering of 8,538,750 shares, reflecting the full exercise of the underwriters’ option to purchase 1,113,750 additional shares, of common stock by Celldex Therapeutics, Inc. The offering priced on November 7, 2023 and closed on November 10, 2023. Celldex received approximately $230.5 million in gross proceeds, excluding underwriting discounts and commissions and other offering-related expenses.

The WilmerHale team representing the underwriters included Lisa Firenze, Scott Lunin, Liz Graffeo, and Giancarlos Rodriguez with assistance from Bruce Manheim on regulatory matters and Barish Ozdamar on intellectual property matters.